Inebilizumab Disease Interactions
There are 4 disease interactions with inebilizumab:
Inebilizumab (Includes inebilizumab) ↔ hepatitis B
Major Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis
The use of inebilizumab is contraindicated in patients with active hepatitis B infection.
Inebilizumab (Includes inebilizumab) ↔ tuberculosis
Major Potential Hazard, Moderate plausibility. Applies to: Tuberculosis -- Active, Tuberculosis -- Latent
The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.
Inebilizumab (Includes inebilizumab) ↔ infections
Moderate Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral
An increased risk of infections has been observed with the use of inebilizumab. It is recommended to delay administration in patients with an active infection until the infection is resolved. Perform HBV screening in all patients before initiation of treatment. Do not administer this agent to patients with active hepatitis. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating treatment. Consider anti-tuberculosis therapy in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consult infectious disease experts regarding whether initiating therapy is appropriate before starting treatment.
Inebilizumab (Includes inebilizumab) ↔ vaccination
Moderate Potential Hazard, Moderate plausibility. Applies to: Vaccination
The use of live attenuated-vaccines or live vaccines is not recommended during treatment with inebilizumab until B-cell repletion. Administer all required immunizations at least 4 weeks prior to initiation of inebilizumab. The safety of immunization with live or live-attenuated vaccines following inebilizumab therapy has not been studied, therefore it is not recommended during treatment until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to inebilizumab during pregnancy before confirming recovery of B-cell counts. Non-live vaccines, may be administered prior to recovery from B-cell and immunoglobulin level depletion, but to assess whether a protective immune response was mounted, consultation with a qualified specialist should be considered.
Inebilizumab drug interactions
There are 102 drug interactions with inebilizumab
More about inebilizumab
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: selective immunosuppressants
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
